TWOCELLS Company

history

TOP > Company > History
August 2000 Japan Science and Technology Agency, a pre-venture project, formed the Bone and Cartilage Regenerative Medicine Team (Professor Yukio Kato, Team Leader and Dr. Koichiro Tsuji, Sub-leader) in Hiroshima University Faculty of Dentistry.
April 2003 TWOCELLS COMPANY, LIMITED. was established as a venture business out of Hiroshima University. Koichiro Tsuji was assigned to be President and CEO. Opened head office at Minami-ku Hiroshima City.
July 2003 Japan Science and Technology Agency pre-venture project completed.
August 2003 Research and development business started.
December 2004 TWOCELLS COMPANY, LIMITED. announced the appointment of Dr. Yukio Kato, Professor, Department of Dental and Medical Biochemistry, Graduate School of Biomedical Sciences, Hiroshima University, to Director. In his new position as Director, he will assume responsibility for the research and development function by a new system.
May 2005 Entered into a licensing agreement with DENTSPLY International Inc.(USA).
December 2005 Appointed Professor Hidemi Kurihara, Graduate School of Biomedical Science, Hiroshima University, as Director of Clinical Research.
April 2006 Tokyo Office had opened (Yushima, Bunkyo-ku, Tokyo).
June 2006 President Tsuji, Directors Kato and Kurihara are awarded a special recognition from Chugoku Region Conference. (Cluster Corporation Symposium which is aimed for industry-government-university co-operation in Chugoku region of Japan) Award name: Distinguished Service Medal to University-generated Venture Co.
August 2006 Registered “gMSC®” as a trademark.
June 2007 Audit & Supervisory Board Member changed. Appointed Audit & Supervisory Board Member Yukio Matsuoka.
April 2008 The organization was restructured.( Research and Development Division/ Sales Engineering Division/ Management Section)
May 2008 Entered into a license agreement with DS Pharma Biomedical Co., Ltd to develop and commercialize STK® 2 (Serum-free culture medium). DS Pharma Biomedical Co., Ltd launched the product STK® 2.
February 2010 Entered into a license agreement with DS Pharma Biomedical Co., Ltd to develop and commercialize STK® 1 (Serum-free culture medium). DS Pharma Biomedical Co. Ltd launched the product STK® 1.
June 2010 Appointed Director Daikichi Nakamura.
September 2010 DS Pharma Biomedical Co. Ltd launched the product STK® 3(for bone differentiation).
June 2011 Appointed Director Tsuyoshi Morishita.
November 2013 Officer changed. Appointed Director Yukio Matsuoka. And appointed Audit & Supervisory Board Member Mitsunobu Kuroda.
January 2014 Opened the gMSC center (Cell Processing Center) to Hiroshima Sangyou Bunka Center Bldg., 2F.
July 2014 TWOCELLS COMPANY, LIMITED. and Chugai Pharmaceutical Co.,Ltd. have entered into the second-order equity agreement. And we have changed the part of the agreement related to the right of first refusal that was entered into agreement in June 2012.
March 2015 Officer changed. Appointed Audit & Supervisory Board Member Minoru Morikawa, and Yuichi Murakami.
April 2015 Moved head office to Hiroshima Sangyou Bunka Center Bldg., 11F.
June 2015 Appointed Audit & Supervisory Board Member Hiroki Mitsui.
December 2015 Appointed Outside director Kiyoshi Ozaki.
©TWOCELLS Company Limited All Rights Reserved.